



# Financial Tear Sheet

## Corporate Profile

AMAG is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives, all while delivering value to our shareholders.

Linda Lennox  
Vice President, Investor  
Relations & Corporate  
Communications

**Phone:** 617-498-2846

**Email:**

[lennox@amagpharma.com](mailto:lennox@amagpharma.com)

Headquartered in Waltham, Massachusetts, with locations in Tucson, Arizona, and San Bruno, California, our products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. In addition, we help families preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders and have the potential to play a valuable role in the ongoing development of regenerative medicine.

Along with driving organic growth of our products, we seek to leverage our existing commercial infrastructure with additional commercial-stage products in our two current therapeutic areas and may consider late-stage development assets or seek opportunities in new therapeutic areas.

## Stock Information

### AMAG (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$17.45</b>
Change (%)	<b>▲ 0.85 (5.12%)</b>
Volume	810,221
52 Week Low	\$16.00
Market Cap	\$585,787,141
Rolling EPS	-1.39
PE Ratio	0



Shares Outstanding 35,288,382

Data as of August 16, 2017 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

## Recent News & Upcoming Events

August 08, 2017

There are currently no events scheduled.

AMAG Pharmaceuticals Appoints Oscar Sanchez as  
Vice President of Quality

August 03, 2017

AMAG Pharmaceuticals Announces Second Quarter  
2017 Financial Results and Provides Corporate  
Update

August 03, 2017

AMAG Completes Feraheme® (ferumoxytol) FDA  
Submission for the Treatment of All Adult Patients  
With Iron Deficiency Anemia

## SEC Filings

Filing Date	Form
August 04, 2017	10-Q
August 03, 2017	8-K
July 31, 2017	SC 13G
July 14, 2017	4